BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings

Bristol Myers Squibb’s highly-anticipated schizophrenia drug KarXT is fast approaching its September FDA decision date, and competition is already heating up in a market that could reach more than $7 billion by 2028.